Prospective study on the relationship between infections and multiple sclerosis exacerbations - PubMed (original) (raw)
Comparative Study
. 2002 May;125(Pt 5):952-60.
doi: 10.1093/brain/awf098.
Affiliations
- PMID: 11960885
- DOI: 10.1093/brain/awf098
Free article
Comparative Study
Prospective study on the relationship between infections and multiple sclerosis exacerbations
D Buljevac et al. Brain. 2002 May.
Free article
Abstract
One of the characteristics of multiple sclerosis is the unpredictable occurrence of exacerbations and remissions. These fluctuations in disease activity are related to alterations in (auto-)immune activity. Exacerbations lead to short-term morbidity, but may also influence long-term disability. This longitudinal study in 73 patients with relapsing-remitting multiple sclerosis assessed the contribution of systemic infections to the natural course of exacerbations. In addition, we analysed whether infections lead to an increase in the number of gadolinium-enhancing lesions. A total of 167 infections and 145 exacerbations were observed during 6466 patient weeks. During a predefined at-risk period (ARP) of 2 weeks before until 5 weeks after the onset of a clinical infection (predominantly upper airway infections), there was an increased risk of exacerbations (rate ratio 2.1), which is in accordance with previous studies. Exacerbations with onset during the ARP led more frequently to sustained deficit [increase of > or =1 Expanded Disability Status Scale (EDSS) point or > or =0.5 above EDSS 5.5 for >3 months] than exacerbations with onset outside the ARP, with a rate ratio of 3.8. Minor and major exacerbations were equally distributed between the ARP and non-ARP onset groups. ARP exacerbations were associated with significantly higher plasma levels of the inflammatory marker soluble intracellular adhesion molecule 1 than non-ARP exacerbations, indicating relatively enhanced immune activation during ARP relapses. Three serial MRI scans were performed after the onset of an infection over a 6-week period. There was no difference in the number of gadolinium-enhancing lesions between the three time points. In conclusion, exacerbations in the context of a systemic infection lead to more sustained damage than other exacerbations. There is no indication that this effect occurs through enhanced opening of the blood-brain barrier.
Comment in
- Infections and the risk of relapse in multiple sclerosis.
Confavreux C. Confavreux C. Brain. 2002 May;125(Pt 5):933-4. doi: 10.1093/brain/awf146. Brain. 2002. PMID: 11960883 No abstract available.
Similar articles
- Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X. Río J, et al. Mult Scler. 2008 May;14(4):479-84. doi: 10.1177/1352458507085555. Mult Scler. 2008. PMID: 18562504 Clinical Trial. - MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C. Gasperini C, et al. Mult Scler. 2002 Apr;8(2):119-23. doi: 10.1191/1352458502ms788oa. Mult Scler. 2002. PMID: 11990868 - Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ, Figgitt DP. Scott LJ, et al. CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review. - Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Coles AJ, et al. Lancet Neurol. 2011 Apr;10(4):338-48. doi: 10.1016/S1474-4422(11)70020-5. Lancet Neurol. 2011. PMID: 21397567 Clinical Trial. - Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ. Fox EJ. Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review.
Cited by
- COVID-19 vaccination in patients with multiple sclerosis: what you need to know - a review.
Mahmoudi F, Mirmosayyeb O, Shaabani E, Ghaffary EM, Nelson F. Mahmoudi F, et al. Health Sci Rep. 2024 Oct 6;7(10):e70119. doi: 10.1002/hsr2.70119. eCollection 2024 Oct. Health Sci Rep. 2024. PMID: 39377025 Free PMC article. - De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate.
Gudesblatt M, Bumstead B, Buhse M, Zarif M, Morrow SA, Nicholas JA, Hancock LM, Wilken J, Weller J, Scott N, Gocke A, Lewin JB, Kaczmarek O, Mendoza JP, Golan D. Gudesblatt M, et al. Adv Ther. 2024 Aug;41(8):3059-3075. doi: 10.1007/s12325-024-02902-0. Epub 2024 Jun 11. Adv Ther. 2024. PMID: 38861218 Free PMC article. - Systemic inflammation associates with and precedes cord atrophy in progressive multiple sclerosis.
Stuart CM, Varatharaj A, Zou Y, Darekar A, Domjan J, Gandini Wheeler-Kingshott CAM, Perry VH, Galea I. Stuart CM, et al. Brain Commun. 2024 Apr 20;6(3):fcae143. doi: 10.1093/braincomms/fcae143. eCollection 2024. Brain Commun. 2024. PMID: 38712323 Free PMC article. - COVID-19 Vaccination Coverage and Associated Factors in Patients with Multiple Sclerosis.
Hernández-García I, Rodríguez-Montolio J, Almeida-Zurita M, Cheli-Gracia D, Sahuquillo BDM, Aibar-Remón C, Garcés-Redondo M. Hernández-García I, et al. Vaccines (Basel). 2024 Jan 26;12(2):126. doi: 10.3390/vaccines12020126. Vaccines (Basel). 2024. PMID: 38400109 Free PMC article. - SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
Di Filippo M, Ferraro D, Ragonese P, Prosperini L, Maniscalco GT, Gallo A, Cavalla P, Lorefice L, Nociti V, Di Sabatino E, Clerico M, Guaschino C, Radaelli M, Fantozzi R, Buttari F, Laroni A, Gajofatto A, Calabrese M, Malucchi S, Paolicelli D, De Luca G, Tomassini V, Lanzillo R, Moccia M, Solaro C, Cocco E, Gasperini C, Tortorella C; RIREMS (Rising Researchers in MS) group. Di Filippo M, et al. J Neurol. 2024 Jan;271(1):24-31. doi: 10.1007/s00415-023-12034-0. Epub 2023 Nov 3. J Neurol. 2024. PMID: 37922069 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous